Lakefront Biotherapeutics NV share price today

Lakefront Biotherapeutics NV's share price was $34.09 at the close on 4 November 2026. It has been stalling near its high for 3 weeks. That is 14.0% above its average price over the last 200 trading days.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Lakefront Biotherapeutics NV is in stage 3. The phase helps read everything below.

In the last 52 weeks it traded between $27 and $34, and at that close it sat 96% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row.

Over the last 10 years the share price moved −38% while the S&P 500 moved +261%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Lakefront Biotherapeutics NV pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Lakefront Biotherapeutics NV is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Lakefront Biotherapeutics NV earned $2.1 M of net profit in the Jun 2026 quarter. Full-year FY25 profit was $321 M. That is 17.4% of the quarter's revenue. The same quarter a year earlier lost $106 M. 4 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY25 profit was $321 M (+333.1% on the year before).

Lakefront Biotherapeutics NV reported $12.1 M of revenue in the Jun 2026 quarter, −81.5% on the same quarter a year earlier. Over 4 years it has grown 47.6% a year on average. The last full year, FY25, came in at $1.1 B. The last four reported quarters add to $991 M.

Revenue is everything the company billed its customers in the period.

FY25 revenue was $1.1 B, +303.5% on the year before.

Recent pace: the last four quarters grew −51.3% on average, against 47.6% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +256.3%, against +81.4% a year over the last 8 quarters (accelerating).

Lakefront Biotherapeutics NV's operating margin was −359.3% in the Jun 2026 quarter, 385.8 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −73.2% and 48.1%. The latest quarter is below every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Across 5 years it has been between −73.2% and 48.1%, and FY25's 48.1% is the highest of them.

Why the margin moved: operating margin changed −385.8 percentage points on the year while gross margin changed −221.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years Lakefront Biotherapeutics NV's operations used more cash than they brought in, so cash conversion was −162%, a gap worth watching. In FY25 its operations used $257 M of cash, against $321 M of profit. After $13.7 M of spending on assets, free cash was −$271 M: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Lakefront Biotherapeutics NV does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $49.1 M on assets over the last 3 years. Averaged over those years that is 1.5% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $49.1 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Lakefront Biotherapeutics NV's P/E is 3.4×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +333.7% while the price moved +8.1%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 3 years the price moved −2.7% a year; about +99.2% a year came from earnings growth and about −101.9 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple.

Lakefront Biotherapeutics NV's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 11 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.